CS Diagnostics Corp. Unveils MEDUSA: A Game-Changer in Disinfectant Technology

CS Diagnostics Corp. (OTCQB: CSDX), a global leader in innovative healthcare solutions, has announced the U.S. launch of MEDUSA, a next-generation smart disinfectant product (SDP) designed to revolutionize hygiene practices across various sectors. MEDUSA, approved in key global regions including the EU and the UAE, is set to receive U.S. approval, offering full protection for up to 10 days on touched surfaces in two formulations tailored to diverse industry needs.



The core, alcohol-free formula is safe and effective for use in high-traffic environments such as hotels, schools, public spaces, and sports venues. This formulation addresses the growing demand for effective and safe disinfectant solutions in these sectors, minimizing the risk of alcohol-related issues like skin irritation or flammability. Additionally, an alcohol-based version is specifically formulated for medical settings such as clinics and hospitals, providing a powerful disinfectant solution against pathogens in healthcare environments.

CS Diagnostics Corp. is also in advanced negotiations for a sponsorship deal with one of Europe's most iconic football clubs. This strategic partnership would bring MEDUSA to the forefront of both the sports industry and public spaces worldwide, enhancing its visibility and market penetration. The global disinfectant market is valued at an estimated $8.37 billion in 2025, with strong demand driven by growing global health and safety concerns, particularly in a post Covid-19 world.

Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented on the company's ambitious plans: "By launching MEDUSA, we aim to achieve $80 million in revenue in 2025, beginning with B2B sales and expanding to B2C by Q3 2025. Our projections indicate $460 million in revenue within three years. In 2025, we plan to enter five markets, with a goal of expanding to 15 markets within three years. By introducing our smart approach to preventing the spread of diseases, we aim to capture 10% of the existing disinfectant market."



In conclusion, CS Diagnostics Corp.'s launch of MEDUSA in the U.S. marks a significant milestone for the company, as it seeks to improve hygiene standards across industries. With its long-lasting protection, safety features, and strategic partnership with a leading European football club, MEDUSA is poised to capture a substantial share of the global disinfectant market. As investors look for high-growth opportunities, CS Diagnostics Corp. offers an attractive investment proposition, ensuring long-term shareholder value by creating and executing impactful, market-leading solutions.